SOPHiA GENETICS (SOPH) Competitors $3.17 -0.10 (-3.06%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SOPH vs. CRBU, VTYX, RPTX, VXRT, FHTX, ETNB, TYRA, RAPP, RLAY, and ERASShould you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Caribou Biosciences (CRBU), Ventyx Biosciences (VTYX), Repare Therapeutics (RPTX), Vaxart (VXRT), Foghorn Therapeutics (FHTX), 89bio (ETNB), Tyra Biosciences (TYRA), Rapport Therapeutics (RAPP), Relay Therapeutics (RLAY), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry. SOPHiA GENETICS vs. Caribou Biosciences Ventyx Biosciences Repare Therapeutics Vaxart Foghorn Therapeutics 89bio Tyra Biosciences Rapport Therapeutics Relay Therapeutics Erasca SOPHiA GENETICS (NASDAQ:SOPH) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation. Does the media prefer SOPH or CRBU? In the previous week, Caribou Biosciences had 4 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 6 mentions for Caribou Biosciences and 2 mentions for SOPHiA GENETICS. Caribou Biosciences' average media sentiment score of 0.45 beat SOPHiA GENETICS's score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in SOPH or CRBU? 31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, SOPH or CRBU? SOPHiA GENETICS has higher revenue and earnings than Caribou Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSOPHiA GENETICS$62.37M3.32-$78.98M-$1.09-2.91Caribou Biosciences$34.48M5.15-$102.07M-$1.65-1.19 Which has more volatility & risk, SOPH or CRBU? SOPHiA GENETICS has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Does the MarketBeat Community prefer SOPH or CRBU? Caribou Biosciences received 5 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 72.00% of users gave SOPHiA GENETICS an outperform vote while only 58.97% of users gave Caribou Biosciences an outperform vote. CompanyUnderperformOutperformSOPHiA GENETICSOutperform Votes1872.00% Underperform Votes728.00% Caribou BiosciencesOutperform Votes2358.97% Underperform Votes1641.03% Do analysts rate SOPH or CRBU? SOPHiA GENETICS presently has a consensus target price of $6.50, indicating a potential upside of 105.05%. Caribou Biosciences has a consensus target price of $11.25, indicating a potential upside of 473.98%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SOPH or CRBU more profitable? SOPHiA GENETICS has a net margin of -110.71% compared to Caribou Biosciences' net margin of -1,290.81%. Caribou Biosciences' return on equity of -45.46% beat SOPHiA GENETICS's return on equity.Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS-110.71% -55.06% -38.33% Caribou Biosciences -1,290.81%-45.46%-38.07% SummaryCaribou Biosciences beats SOPHiA GENETICS on 12 of the 17 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get SOPHiA GENETICS News Delivered to You Automatically Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SOPH vs. The Competition Export to ExcelMetricSOPHiA GENETICSBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$213.78M$2.93B$5.07B$8.89BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-2.9115.0083.5712.93Price / Sales3.32280.711,220.3088.33Price / CashN/A168.0739.4636.25Price / Book1.824.696.936.25Net Income-$78.98M-$41.63M$119.12M$225.93M7 Day Performance-14.32%-4.73%-1.83%-1.32%1 Month Performance-5.93%-6.53%-3.64%0.60%1 Year Performance-17.88%25.63%31.64%26.23% SOPHiA GENETICS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SOPHSOPHiA GENETICS1.4237 of 5 stars$3.17-3.1%$6.50+105.0%-14.6%$213.78M$62.37M-2.91520CRBUCaribou Biosciences2.9283 of 5 stars$1.96-1.5%$11.25+474.0%-64.7%$180.20M$34.48M0.00100VTYXVentyx Biosciences2.4784 of 5 stars$1.72-3.4%$10.00+481.4%-27.1%$125.86MN/A-0.7373RPTXRepare Therapeutics2.672 of 5 stars$2.84-1.4%$10.00+252.1%-44.7%$122.43M$51.13M0.00180VXRTVaxart2.1372 of 5 stars$0.61-1.6%$3.00+393.6%-22.1%$110M$7.38M-1.48109Analyst RevisionNews CoverageFHTXFoghorn Therapeutics2.6424 of 5 stars$7.86+0.8%$16.00+103.6%+91.2%$433.63M$34.15M0.00120ETNB89bio1.4925 of 5 stars$7.98-0.1%$30.33+280.1%+3.1%$847.95MN/A0.0040TYRATyra Biosciences3.0757 of 5 stars$15.87-2.1%$31.00+95.3%+40.8%$820.27MN/A0.0020RAPPRapport Therapeutics1.8437 of 5 stars$22.19-0.4%$35.00+57.7%N/A$814.92MN/A0.00N/ANews CoverageRLAYRelay Therapeutics3.2712 of 5 stars$4.66-2.9%$21.22+355.4%-44.5%$803.44M$25.55M0.00304Gap DownHigh Trading VolumeERASErasca2.8027 of 5 stars$2.64-5.4%$6.08+130.4%+17.3%$788.81MN/A0.00126Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies CRBU Alternatives VTYX Alternatives RPTX Alternatives VXRT Alternatives FHTX Alternatives ETNB Alternatives TYRA Alternatives RAPP Alternatives RLAY Alternatives ERAS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SOPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SOPH Stock Alerts